$FGBI

Louisiana bank faces unusual limits on who it can lend to

First Guaranty Bank, a Louisiana lender and subsidiary of First Guaranty Bancshares, agreed to a consent order with the FDIC and Louisiana regulators restricting additional credit to certain borrowers and requiring loan documentation, monitoring, and capital improvements. The bank reported $6.2 million net income for the first six months of 2026. Its shares fell over 12% to $8.42 after the order. A Texas branch sale completed Aug. 6 is expected to help raise Tier 1 leverage toward a 9% requireme

Original reporting
Published Aug 11, 2026, 2:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 2:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Louisiana bank faces unusual limits on who it can lend to — source image
Decision brief

The 30-second read

$FGBIBearishMed
01

Why it matters

The consent order adds unusual, borrower-specific lending restrictions tied to charge-offs/loss classifications and “doubtful” or “substandard” credit categories, alongside requirements to upgrade loan documentation, monitoring, and stress testing. It also sets a concrete capital target (Tier 1 leverage to 9%), while a recent branch sale is expected to help close the gap.

02

Market read

Traders should focus on compliance trajectory: whether the branch-sale capital boost and continued criticized-loan reductions can credibly move the bank toward the 9% Tier 1 leverage requirement, despite lending restrictions.

03

What to watch

The article notes “full compliance” with most consent-order items except the Tier 1 leverage ratio, so the market may be over-discounting the remaining capital step relative to the bank’s progress on nonperforming assets.

Relevance 7/10Novelty 6/10Timing: post-consent-order filing, with branch-sale capital boost completed Aug. 6 and stock reaction on Monday

Background

First Guaranty Bank, a $3.9B-asset Hammond, Louisiana lender, has been dealing with credit-quality issues and entered a consent order with the FDIC and Louisiana’s Office of Financial Institutions.

Company-level read

Ticker impact

$FGBIBearishMedium confidence
Context

First Guaranty agreed to an FDIC and Louisiana consent order that restricts lending to certain borrower credit profiles and requires capital actions.

Expected impact

Near-term downside bias or elevated volatility versus peers, with relief only if capital ratio improvement and criticized-loan reductions continue.

Evidence & confidence

The article describes rarely seen customer-lending limits plus a specific capital ratio requirement (to 9%), and notes the stock fell more than 12% on the consent-order news.

Market effects

Highlights heightened regulatory scrutiny and potential for similar consent-order structures among smaller banks with elevated criticized loans.

Louisiana-focused regulator involvement may increase attention on regional bank credit quality and capital compliance.

Limited direct global impact, but reinforces broader US bank-regulatory tightening risk for small-cap lenders.

Counterpoint

If the branch sale meaningfully lifts Tier 1 leverage and the bank sustains criticized-loan declines, the restrictions could be viewed as a contained, solvable compliance path rather than a deterioration signal.

Key entities

  • First Guaranty Bank

    Subject of the FDIC and Louisiana consent order restricting additional credit to certain borrowers and requiring capital ratio improvement.

  • FDIC

    Co-issuer of the consent order imposing lending and capital requirements.

  • Armstrong Bank

    Buyer of five Texas branches from First Guaranty, expected to boost Tier 1 leverage.

  • First Guaranty Bancshares

    Parent company referenced as the entity tied to the consent-order requirements.

Related articles

$FGBIHigh

First Guaranty Bancshares, Inc. Announces Third Quarter 2026 Financial Results

First Guaranty Bancshares, Inc. (FGBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 OCTOBER 27, 2026 NEWS FOR IMMEDIATE RELEASE CONTACT: ERIC J. DOSCH, CFO 985.375.0308 First Guaranty Bancshares, Inc. Announces Third Quarter 2026 Financial Results Hammond, Louisiana , October 27, 2026 – First Guaranty Bancshares, Inc. ("First Guaranty") (NASDAQ: FGB

$FGBILow

First Guaranty Bancshares, Inc. (FGBI): Results of Operations and Financial Condition

First Guaranty Bancshares, Inc. (FGBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. PR ES O R TE D FI R ST -C LA SS M A IL U. S. P O ST AG E PA ID B AT O N R O UG E, L A PE R M IT N O . 9 84 Total Assets $3.9 Billion Deposits $3.5 Billion Locations 30 ATMs 40 $3.4 Million 2Q 2026 Earnings $6.2 Million YTD2026 Earnings 132 Consecutive dividends paid and counting

$FGBIMed

First Guaranty Bancshares, Inc. Announces Second Quarter 2026 Financial Results

First Guaranty Bancshares, Inc. (FGBI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 fgbi-ex991earningspressrel.htm EX-99.1 PRESS RELEASE Document EXHIBIT 99.1 JULY 27, 2026 NEWS FOR IMMEDIATE RELEASE CONTACT: ERIC J. DOSCH, CFO 985.375.0308 First Guaranty Bancshares, Inc. Announces Second Quarter 2026 Financial Results Hammond, Louisiana , July 27, 202

$ECORMed

electroCore submits FDA 510(k) application for CIPN device

electroCore (NASDAQ:ECOR) submitted a 510(k) application to the FDA for its Quell device to treat chemotherapy-induced peripheral neuropathy (CIPN). The submission is based on two studies showing pain score reductions and improvements in neuropathy symptoms. FDA clearance is not guaranteed, and Quell is not currently approved for CIPN.

$ECORMed

electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)

electroCore, Inc. (ECOR) submitted a 510(k) premarket notification to the FDA seeking clearance for its Quell® device to treat chronic chemotherapy-induced peripheral neuropathy (CIPN). The submission is supported by clinical studies showing symptom improvements. If cleared, Quell would be among the first FDA-cleared devices for CIPN. The FDA review process is underway, with no guarantee of clearance.